ArticleInternational journal of inflammation2012
The gut microbiota and irritable bowel syndrome: friend or foe?
Article in International journal of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Efficacy and Safety of Probiotics, Prebiotics and Synbiotics in the Treatment of Irritable Bowel Syndrome: A systematic review and meta-analysis.Sultan Qaboos University medical journal · 2020Pooled it
- Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis.Journal of gastroenterology · 2018Pooled it
- Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome.BMC gastroenterology · 2021Trial
- A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.BMC gastroenterology · 2018Trial
- Small Intestinal Bacterial Overgrowth Following Gastrointestinal Cancer Surgery: Current Evidence and Future Perspectives.Annals of gastroenterological surgery · 2026Review
- Gut microbiota, inflammatory cytokines and gastro-esophageal reflux disease: A Mendelian randomization analysis.Medicine · 2025Article
- The relationship between gut microbiome and human diseases: mechanisms, predisposing factors and potential intervention.Frontiers in cellular and infection microbiology · 2025Review
- Gut microbiota therapy in gastrointestinal diseases.Frontiers in cell and developmental biology · 2025Review
- Oral Health and "Modern" Digestive Diseases: Pathophysiologic and Etiologic Factors.Biomedicines · 2024Review
- Factors associated with irritable bowel syndrome andThe Journal of international medical research · 2024Article
- Impact of low FODMAP sourdough bread on gut microbiota using anFrontiers in microbiology · 2024Article
- Microbiota revolution: How gut microbes regulate our lives.World journal of gastroenterology · 2023Review
- Article
- AQP1 in the Gastrointestinal Tract of Mice: Expression Pattern and Impact of AQP1 Knockout on Colonic Function.International journal of molecular sciences · 2023Article
- Analysis of the gut microbiota in children with gastroesophageal reflux disease using metagenomics and metabolomics.Frontiers in cellular and infection microbiology · 2023Article
- Effects of urbanization and lifestyle habits on the intestinal microbiota of adolescents in eastern China.Frontiers in microbiology · 2023Article
- Effect of Microgravity on the Gut Microbiota Bacterial Composition in a Hindlimb Unloading Model.Life (Basel, Switzerland) · 2022Article
- Postinfection Irritable Bowel Syndrome.Gut and liver · 2022Review
- Role of the gut microbiome in chronic diseases: a narrative review.European journal of clinical nutrition · 2022Review
- Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia.International journal of molecular sciences · 2022Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progress in the understanding of the pathophysiology of irritable bowel syndrome (IBS), once thought to be a purely psychosomatic disease, has advanced considerably and low-grade inflammation and changes in the gut microbiota now feature as potentially important. The human gut harbours a huge microbial ecosystem, which is equipped to perform a variety of functions such as digestion of food, metabolism of drugs, detoxification of toxic compounds, production of essential vitamins, prevention of attachment of pathogenic bacteria to the gut wall, and maintenance of homeostasis in the gastrointestinal tract. A subset of patients with IBS may have a quantitative increase in bacteria in the small bowel (small intestinal bacterial overgrowth). Qualitative changes in gut microbiota have also been associated with IBS. Targeting the gut microbiota using probiotics and antibiotics has emerged as a potentially effective approach to the treatment of this, hitherto enigmatic, functional bowel disorder. The gut microbiota in health, quantitative and qualitative microbiota changes, and therapeutic manipulations targeting the microbiota in patients with IBS are reviewed in this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.